Skip to main content
Fig. 1 | BMC Neurology

Fig. 1

From: Chronic inflammatory demyelinating polyneuropathy and psoriasis comorbidity with significantly alleviated in symptoms after secukinumab: case report

Fig. 1

Schematic diagram of symptom relief-recurrence fluctuation after immunomodulatory treatment. After each IVIG treatment, the symptoms improved, and the MRC sum scores were increased by ≥ 6 points. The patient was treated with secukinumab on September 27th, 2021, at a dose of 300 mg subcutaneous injection (1 time/week, for 5 weeks). During the follow-up, the patient's clinical symptoms have been stabilized for a significantly longer period of time than before. (Abbreviations: IVIg: intravenous injections of human immunoglobulin G; IA: immunoadsorption)

Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us